Neomorph raises $100M to push its first molecular glue degrader into the clinic
What's the deal? San Diego-based Neomorph has closed a $100 million Series B to advance its pipeline of molecular glue degraders — a class of drugs that work by essentially instructing the body's own cellular machinery to destroy disease-causing proteins that conventional medicines cannot reach.
The round was led by Deerfield Management, Neomorph's founding investor, with new participants including Regeneron VenturesDealroom has a profile for this one. Try Dealroom → and Binney Street CapitalDealroom has a profile for this one. Try Dealroom →, the investment arm of the Dana-Farber Cancer InstituteDealroom has a profile for this one. Try Dealroom →. The company was founded in 2020.
Proceeds will primarily fund the ongoing Phase 1/2 clinical trial of NEO-811, Neomorph's lead asset, for a form of kidney cancer called clear cell renal cell carcinoma (ccRCC), as well as broader pipeline development.
Why now? Neomorph dosed its first patient in the NEO-811 trial in February 2026 — a key clinical milestone that de-risks the programme and justifies fresh capital. The trial is evaluating the drug as a monotherapy in patients with locally advanced or metastatic ccRCC, a disease with limited treatment options at late stage.
The raise also reflects strong validation from the pharma industry. Novo Nordisk, Biogen, and AbbVie have all partnered with Neomorph across cardiometabolic disease, rare disease, neurology, oncology, and immunology — a breadth of partnerships that signals the platform's versatility beyond any single indication.
What could go wrong? Molecular glue degraders are a genuinely novel drug class, which means the clinical and regulatory path is less well-mapped than for conventional small molecules or biologics. NEO-811 is the first molecular glue degrader to enter a clinical trial targeting ARNT — a protein implicated in kidney cancer — and first-in-human trials carry inherent uncertainty around safety and tolerability. A setback at this stage would be costly both financially and reputationally.
The company is also still early: six years old, Series B, with a lead asset in Phase 1/2. The distance to a commercially approved drug is long and capital-intensive.
The signal: Neomorph's raise reflects accelerating investment in targeted protein degradation — a field that has moved from academic curiosity to serious drug discovery category in under a decade. The underlying logic is compelling: most disease-causing proteins are considered "undruggable" by conventional methods, meaning there is no small molecule that can block them effectively. Molecular glues and related technologies like PROTACs offer a way around that constraint by co-opting the cell's own disposal system.
The involvement of Dana-Farber's investment arm and Regeneron Ventures alongside Deerfield signals that both academic cancer medicine and commercial drug development are converging on this platform as a credible path to new medicines.
Sources:
Neomorph
GlobeNewswire
Business Insider
The Hamilton Spectator
Manila Times
J.V.
